• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Infliximab
    3 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Ixifi®
    Pfizer
    RX
    not in the basket chart
    Ixifi®

    TNF-A Inhibitors. Infliximab 100 mg.
    VIAL: 1,2,3,5×15 ml. Dosage should be ajust. individ. according to the pt. medical cond. See lit.
    RA: In comb. with methotrexate- reduct. of signs and sympt. as well as the improve. in physical funct. in:
    Adult pts. with active dis. when the response to dis. modif. antirheum. drugs (DMARDs), includ. methotrexate, has been inadeq.
    Adult pts. with severe, active and progress. dis. not previous. treated with methotrexate or other DMARDs. In these pt. populations, a reduct. in the rate of the progres. of joint damage, as measured by X ray, has been demonstr.
    Ankylosing spondylitis: Tmt. of severe, active ankylos. spondylitis, in adult pts. who have responded inadeq. to convent. ther.
    Psoriatic arthritis: Tmt. of active and progres. psoriat. arthritis in adult pts. when the response to previous DMARD ther. has been inadeq. the drug should be admin. in comb. with methotrexate or alone in pts. who show intoler. to methotrexate or for whom methotrexate is contraind.
    Infliximab has been shown to improve physical func. in pts. with psoriat. arthrit., and to reduce the rate of progress. of peripher. joint damage as measured by X ray in pts. with polyarticular symmetry. subtypes of the dis.
    Psoriasis: Tmt. of moder. to sev. plaque psorias. in adult pts. who failed to respond to, or who have a contraindicat. to, or are intolerant. to other system. ther. include, cyclosporine, methotrexate or psoralen ultra-violet A (PUVA).
    Adult Crohn’s dis.: Moder. to sever. active Crohn’s dis., in adult pts. who have not respond. despite a full and adequate course of ther. with a corticosteroid and/or an immunosuppressant; or who are intoler. to or have med. contraindicate. for such therapies. Tmt. of fistulising, active Crohn’s dis., in adult pts. who have not responded despite a full and adequate course of ther.  with convent. tmt. (includ. antibiotics, drainage and immunosuppressive ther.).
    Ulcer. colitis: Tmt. of moder. to sever. active ulcerat. colitis in adult pts. who have had an inadeq, response to convent. ther. includ. corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intoler. to or have medical contraindicat. for such therapies.
    C/I: Hypersens. the active substance, to other murine proteins. Pts. with tuberculosis or other severe infec. such as sepsis, abscesses, and opportunis. infec. Pts. with moder. /severe HF (NYHA class III/IV).

    Remicade
    Janssen
    RX
    partial basket chart
    Remicade

    Monoclonal Antibody. Infliximab 100 mg/vial.
    VIALS: 1. Rheum. arthrit: Pts. not prev.
    treated: 3 mg/kg I.V. infus. over 2 hr,
    foll. by addit. 3 mg/kg infus. 2 wks and6 wks aft. first infus., then every 8
    wks,concom. with methotrexate.
    Severeactive CD: 5 mg/kg I.V. over 2 hrs.
    Maint: Addit. infus. 5 mg/kg at 2 and
    6wks. aft. initial dose, foll. by infus.every
    8 wks or: readmin: infus: 5 mg/kgif recur.
    See lit. Fistuliz. active CD: Initial 5 mg/kg
    over 2 hrs, follow. by 5mg/kg at 2 and 6
    wks after 1st infus.No addit. tmt. if no
    response after 3doses. See lit. Ulc. colit:
    5 mg/kg I.V.infus. over 2 hr. foll. by addit.
    5 mg/kginfus. at 2 and 6 wks aft. 1st
    infus., thenevery 8 wks. thereaft.
    Ankylos.spondilit: 5 mg/kg I.V. infus.
    over 2 hrs.foll. by addit. 5 mg/kg infus at
    2 and 6wks. aft. 1st infus., then every 6-8
    wks.No response aft. 6 wks: No addit.
    tmt.Psor. arthrit: 5 mg/kg I.V. infus. over
    2hrs. foll. by addit. 5 mg/kg at 2 and
    6wks aft. 1st infus., then every 8
    wksthereaft. Psorias: 5 mg/kg I.V. infus.
    over 2 hrs. foll. by addit. 5 mg/kg at
    2and 6 wks aft. 1st infus., then every
    8wks thereaft. No response aft. 14 wks.
    (i.e. 4 doses): No addit. tmt.
    Rheum. arthrit. in comb.
    withmethotrexate: Reduct. signs/
    sympts,improve. physical funct. in: Active
    dis.when response to dis.-
    modifyingdrugs(incl. methotrexate)
    inadequate.
    Severe,active/progress. dis. not prev.
    treated withmethotrexate or other
    DMARDs. Tmt.t of moder.to sev. ,active
    Crohn’s dis., ped. severe,active Crohn’s
    dis.,fistulising activeCrohn’s disease, in
    pts.
    unresponsive tocorticoster. or
    immunosuppress. ther.Ulcerat. colit. (mod.-
    severe), pediatricseverely active ulcerat.
    colit.; ankylos.spondylit., psoriat. arthrit.,
    psoriasis.
    Adult: Crohn’s disease: Treatment of
    moderate to severe active Crohn’s disease in
    patients who have not responded despite of
    a full and adequate course of therapy with a
    corticosteroid and/or an
    immunosuppressant. For full details see lit.
    C/I: Pts. with a hist.of hypersens.
    to infliximab ,to other murine prot. Pts.
    with tuberculosis or other sev. infec.
    (sepsis, abscesses, opportun. infec.) Pts.
    with mod., sev. heart fail. (NYHA class III/
    IV).

    Remsima
    Perrigo
    RX
    partial basket chart
    Remsima

    TNF-A Inhibitors. Infliximab 100 mg / 10 ml.
    VIAL (Pwdr. for concentr. for sol.for infus.):20ml. Dosage must be ajust. individ. accord. to pt. med. cond.
    RA: in comb.with methotrexate, for the reduct. of signs and sympt. as well as the improv. in physic. func. in: Adult pts. with active dis. when the response to DMARDs, include. methotrexate, has been inadeq. Adult pts. with sev., act. and progres. dis. not prev. treated with methotrexate or other DMARDs. In these pt. populations, a reduct. in the rate of the progres. of joint damage, as measured by X‑ray, has been demonst. Ankylos. spondyl.:tmt. of sev., act. ankyl. spondyl., in adult pts. who have responded inadeq. to convent. ther. Psoriatic arthr. tmt. of active and progres.  psoriatic arthr. in adult pts. when the response to prev. DMARD ther. has been inadeq. Infliximab  should be admin. in comb. with methotrexate. Or alone in pts. who show intoler. to methotrexate or for whom methotrexate is contraind.
    C/I: Pts. with a history of hypers. to infliximab or to other murine proteins. Pts. with tuberculosis or other sev. infect.  such as sepsis, abscesses, and opportunistic infect. Pts. with moder./ or sev. heart fail. (NYHA class III/IV).

    CLOSE